Microchip Based Isolation and Drug Delivery of Patient‐Derived Extracellular Vesicles Against Their Homologous Tumor
Authors:
- 2 September 2024
- journal article
- research article
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (30) , e2401990
Abstract
Extracellular vesicles (EVs) have demonstrated significant potential in drug delivery and anti‐tumor therapy. Despite this promising strategy, challenges such as specific targeting, EVs purification persist. In this study, a personalized nanodrug delivery platform using patient‐derived tumor EVs (PT‐EVs) based on a microchip is presented. The microchip integrates multiple functions, including capture, enrichment, drug loading, and elution of PT‐EVs. The isolation and drug‐carrying procedures are completed within a 12 h timeframe, achieving a recovery rate of 65%, significantly surpassing the conventional ultracentrifuge (UC) method. Furthermore, PT‐EVs derived from patient tumor models are first utilized as natural drug carriers, capitalizing on their inherent homing ability to precisely target homologous tumors. Lenvatinib and doxorubicin (DOX), two commonly utilized drugs in the clinical treatment of hepatocellular carcinoma (HCC), are loaded into PT‐EVs and delivered to a matched in vitro tumor model that recapitulates original tumors for drug susceptibility testing. As is proven, PT‐EVs exhibit robust tumor cell targeting and efficient receptor‐mediated cellular uptake, and the efficacy of chemotherapeutic drugs is improved significantly. These results suggest that this platform could be a valuable tool for efficient isolation of PT‐EVs and personalized drug customization, particularly when working with limited clinical samples, thus supporting personalized and precision medicine.Keywords
Funding Information
- National Natural Science Foundation of China (22174126, 21874116)
This publication has 34 references indexed in Scilit:
- Integrated microfluidic system for isolating exosome and analyzing protein marker PD-L1Biosensors and Bioelectronics, 2022
- Microfluidic device for one-step detection of breast cancer-derived exosomal mRNA in blood using signal-amplifiable 3D nanostructureBiosensors and Bioelectronics, 2022
- Liposome composition in drug delivery design, synthesis, characterization, and clinical applicationAdvanced Drug Delivery Reviews, 2021
- The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironmentBioactive Materials, 2021
- Berberine-loaded M2 macrophage-derived exosomes for spinal cord injury therapyActa Biomaterialia, 2021
- Tumor Exosomes Reprogrammed by Low pH Are Efficient Targeting Vehicles for Smart Drug Delivery and Personalized Therapy against their Homologous TumorAdvanced Science, 2021
- Intratumor Heterogeneity: The Rosetta Stone of Therapy ResistanceCancer Cell, 2020
- Isolation and Profiling of Circulating Tumor‐Associated Exosomes Using Extracellular Vesicular Lipid–Protein Binding Affinity Based Microfluidic DeviceSmall, 2019
- Extracellular vesicles for drug deliveryAdvanced Drug Delivery Reviews, 2016
- Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug deliveryJournal of Controlled Release, 2014